HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account

David Avigan, MD

Professor of Medicine, Harvard Medical School, Chief of the section of the Hematologic Malignancy and Bone Marrow Transplant Program at Beth Israel Deaconess Medical Center. Director of the Cancer Vaccine Program, Director of the Allogeneic Transplant from Unrelated Donors Program, Director of the Cord Blood Transplant Program.

Clinical Expertise

My research interest lies in the field of tumor immunotherapy and its incorporation into bone marrow transplantation. Active projects include the development of dendritic cell tumor fusions to be used as tumor vaccines in a clinical trial for patients with breast cancer now in progression. I have also been exploring the number of immune reconstitution post-transplant and studying the impact of cytokine therapy with IL-12 and GM-CSF on this process. I am currently leading a new trial in the use of post-transplant Her2Neu antibody therapy assessing its impact on persistent residual disease. One group is investigating novel approaches to allogeneic transplantation including the use of non-myeloablative approaches.


Beth Israel Deaconess Medical Center: 330 Brookline Ave, Boston, MA 02115, USA

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube